Literature DB >> 22434250

Experimental arthritis: Targeted anti-C5 drug neutralizes complement in the joint.

Emma Leah.   

Abstract

Entities:  

Year:  2012        PMID： 22434250     DOI： 10.1038/nrrheum.2012.31

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5.

Authors:  Paolo Macor; Paolo Durigutto; Luca De Maso; Chiara Garrovo; Stefania Biffi; Andrea Cortini; Fabio Fischetti; Daniele Sblattero; Costantino Pitzalis; Roberto Marzari; Francesco Tedesco
Journal:  Arthritis Rheum       Date:  2012-08
  1 in total
  1 in total

Review 1.  Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.

Authors:  Katherine E Lintner; Yee Ling Wu; Yan Yang; Charles H Spencer; Georges Hauptmann; Lee A Hebert; John P Atkinson; C Yung Yu
Journal:  Front Immunol       Date:  2016-02-15       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.